L’ENTREPRISE

Cerebriu a été fondée en 2018.

Nous automatisons l’exécution des examens IRM tout en y infusant de l’intelligence clinique au plus proche du patient, pendant son examen d’imagerie. Notre mission est d’optimiser les flux de travail des radiologues, technologues et cliniciens tout en les soulageant de tâches répétitives.

La diversité catalyse
la créativité

nationalités

Le savoir est source
de progrès

personnes avec PhD ou MD

Ensemble nous
accomplissons d’avantage

« employé(e)s »

LA MISSION DE CEREBRIU EST DE SIMPLIFIER LA RADIOLOGIE EN INFUSANT DE L’INTELLIGENCE CLINIQUE AU PLUS PROCHE DU PATIENT, PENDANT SON EXAMEN D’IMAGERIE

Nos principaux objectifs sont l'optimisation des flux de travail et l'acquisition des images adéquates pour le patient adéquat au moment adéquat.

Cerebriu améliore les flux de travail en suggérant, de façon automatisée, les séquences IRM les plus adéquates à acquérir, alors que le patient est toujours dans le scanner. Le logiciel identifie également les anomalies critiques lors des phases initiales de l’examen, permettant ainsi une analyse radiologique rapide et une prise en charge du patient de meilleur qualité.

En utilisant le logiciel d’intelligence artificielle développé par Cerebriu, le personnel médical peut s'attendre à une réduction des sollicitations des radiologues en rapport avec l'élaboration des protocoles, une plus grande autonomie et assurance des technologues, une réduction du stress professionnel, une baisse du nombre de séquences acquises superflues, une interprétation plus rapide des examens critiques et une communication plus rapide et efficace avec l’équipe soignante.

Depuis 2020, Cerebriu s'est engagée à respecter l'initiative de responsabilité d'entreprise du Pacte mondial de l'ONU et ses principes en matière de droits de l'homme, de travail, d'environnement et de lutte contre la corruption.

DIRECTION

Robert Lauritzen

CEO

Robert est l'un des cofondateurs de l’entreprise. Cadre spécialisé dans l’informatique et les sciences de la vie, Robert a plus de 25 ans d’expérience internationale en gestion de start-ups (dans le domaine de l’high-tech et technologies médicales) et de grandes entreprises pharmaceutiques ou prestataires de services informatiques. Tout au long de sa carrière, Robert a mis en place et géré la distribution et les ventes de produits en Europe, aux États-Unis et en Asie.

Martin Lillholm, PhD

Chief Operating Officer

Prof. Lillholm is one of the co-founders and specialised in machine learning at the department of computer science at the University of Copenhagen. Martin holds an extensive background in compliance of medical devices, ensuring licenses to operate, regulatory compliance and quality certification. Previously Prof. Lillholm was the Deputy Head of the Department of Computer Science and worked in the industry. He holds a PhD from IT-University of Copenhagen in computer vision and a master’s from the University of Copenhagen.

Akshay Pai, PhD

CTO

Dr. Pai est l'un des cofondateurs de Cerebriu avec plus d'une dizaine d’année d'expérience en apprentissage machine, en particulier dans le secteur de l'imagerie médicale. Dr. Pai détient plusieurs brevets et est auteur de plus de 50 publications scientifiques.

Amine Korchi

CMO

Neuroradiologist, practicing radiologist, award-winning researcher and tech savvy entrepreneur driving radiology disruption.

Thomas Olesen

Chief Commercial Officer

Thomas is an international digital health executive with +15 years of experience of successfully commercializing and rapidly growing sales of novel healthcare technologies on behalf of startups and Fortune500, big corporates (Qualcomm life). Thomas spent over 14 years working in Germany and the US.

Kristine Wernerfelt

CFO

+15 years’ experience working with the strategic/CXO agenda across industries in a variety of settings across investment management, management consulting, corporate finance, solution selling.

CEREBRIU IN THE US:

Zac Durant

Vice President of BD

Zac has a strong commercial background managing strategic alliances, marketing strategy and brand development, with a focus on the US market. Previously at leading companies such as GE Healthcare, Zac developed business growth strategies within emerging segments for portfolio expansion. Zac holds a BS in Chemical Engineering and BA in Philosophy from University of Massachusetts Lowell.

NOTRE CONSEIL

Peter Savas

–

Président du Conseil

À propos de Peter

Mr. Savas brings over 30 years of experience in executive leadership positions across life sciences. He was CEO of Alseres Pharmaceuticals, Inc., Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® transdermal patch marketed worldwide to treat Parkinson’s disease and Restless Legs Syndrome and Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials. Peter also held executive and operating leadership positions with Bristol Myers, Waters, Millipore, Genex and Zymark. With a personal mission for entrepreneurism and pursuing advancement in neurologic science, Peter bridges strategic and operational healthcare experience with broad access to industry, academia, regulatory and capital markets leaders. Peter holds a BS in Chemistry from Syracuse University and is credentialed as a Professional Director by the American College of Corporate Directors.

Dr. Jonathan Gertler

Board member

About Jonathan

Jonathan P. Gertler joined BioVentures Investors in 2019 and is currently a Managing Director. He has over 35 years of scientific, clinical, entrepreneurial, transactional, and investment expertise in both academic medicine and in the life sciences sector. Dr. Gertler is also the co-founder, Managing Partner and CEO of Back Bay Life Science Advisors, a global life science consultancy and advisory group, and founder of three additional healthcare companies.

Homer Pien

PhD

Membre du conseil

About Homer

Homer Pien currently serves on multiple boards, and was most recently SVP and Chief Scientific Officer at Philips for the Precision Diagnosis cluster of businesses, and prior to that Chief Technology Officer for Imaging System, at Philips as well. Before joining Philips in 2012, he was in the Department of Radiology at Massachusetts General Hospital and Harvard Medical School, where he led the Laboratory for Medical Imaging and Computations. Homer was also at two start-ups, one of which was a biotech company he co-founded and served as CEO prior to the company being acquired. Earlier in his career Homer was at MIT Lincoln Lab and Draper Lab. Homer has a PhD in computer science from Northeastern University (Boston, MA), and MS Management from Massachusetts Institute of Technology (Cambridge, MA).

Ulrik Spork

–

Membre du conseil

About

Ulrik Spork is active as Chairman, board member, and advisor in several emerging life-science and MedTech companies as well as two venture/PE funds-of-funds. For over 25 years Ulrik held senior positions in the Novo Group, where he effectively executed Novo Nordisk’s corporate development activities. He also founded and led as Senior/Managing Partner the Venture, Growth Equity, and Principal Investment activities in Novo Holdings A/S. He holds a master’s degree in engineering from Danish Technical University.

Claudia Colciago

PhD

Board member

About

Dr. Claudia Maria Colciago is a Senior Investment Manager in Denmark’s Export and Investment Fund and member of several boards. She previously held positions such as Associate Director at Takeda Digital Ventures. Prior to that, at MTIP she led a $20m+ financing round in Oviva and partook in the first and following investment in other portfolio companies such as Coramaze, Blueprint Genetics, Tyto Care, Lumeon, and Cynerio. She has a Ph.D. in Applied Mathematics from the École Polytechnique fédérale de Lausanne (EPFL), and a post-doc, where she led a proof-of-concept project of a digital health start-up.